Regen BioPharma Files 8-K with Corporate Updates

Ticker: RGBPP · Form: 8-K · Filed: May 23, 2024 · CIK: 1589150

Sentiment: neutral

Topics: corporate-governance, filing-update

Related Tickers: RGBP

TL;DR

Regen BioPharma filed an 8-K on 5/23 for a 5/20 event - corporate changes and exhibits filed.

AI Summary

Regen BioPharma Inc. filed an 8-K on May 23, 2024, reporting an event on May 20, 2024. The filing indicates changes to its Articles of Incorporation or Bylaws, other events, and financial statements/exhibits. The company is incorporated in Nevada and its fiscal year ends on September 30.

Why It Matters

This filing signals potential changes in Regen BioPharma's corporate structure or governance, which could impact its operational direction and investor relations.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain immediate negative financial or operational news.

Key Players & Entities

FAQ

What specific changes were made to the Articles of Incorporation or Bylaws?

The filing indicates that amendments to the Articles of Incorporation or Bylaws were made, but the specific details of these amendments are not provided in the excerpt.

What were the 'Other Events' reported on May 20, 2024?

The excerpt states 'Other Events' were reported, but does not specify what those events were.

What financial statements and exhibits are included in this filing?

The filing lists 'Financial Statements and Exhibits' as an item, but the specific contents are not detailed in the provided text.

When is Regen BioPharma Inc.'s fiscal year end?

Regen BioPharma Inc.'s fiscal year ends on September 30.

What is the company's principal executive office address?

The company's principal executive office is located at 4700 Spring Street, St 304, La Mesa, California, 91942.

Filing Stats: 539 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-05-23 09:31:01

Filing Documents

03 Amendments to Articles of Incorporation

Item 5.03 Amendments to Articles of Incorporation On May 20, 2024 Regen Biopharma, Inc. amended its Certificate of Incorporation adding the following Article 8 which is and reads as follows: Shares of one class or series of stock may be issued as a share dividend in respect of another class or series.

01 Other Events

Item 8.01 Other Events. On May 21 , 2024 the Board of Directors of Regen Biopharma, Inc.("Regen") declared a dividend to all shareholders of record as of June 20,2024 ("Record Date") to be paid to shareholders on or about July 1, 2024 such dividend to be payable in shares of the Regen's authorized but unissued Series A Preferred Stock and to consist of two share of Series A Preferred Stock for every one share of Regen Biopharma, Inc. Common Stock owned as of the Record Date, every one share of Regen Biopharma, Inc. Series A Preferred Stock owned as of the Record Date, every one share of Series AA Preferred Stock owned as of the Record Date, every one share of Series M Preferred Stock owned as of the Record Date and every one share of Series NC Preferred Stock owned as of the Record Date

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits Exhibit No. Description Exhibit 3(i) Amendment to Articles of Incorporation 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REGEN BIOPHARMA, INC. Dated: May 23, 2024 By: /s/ David Koos 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing